268 related articles for article (PubMed ID: 31542806)
21. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
Eur Urol; 2020 Oct; 78(4):540-543. PubMed ID: 32660748
[TBL] [Abstract][Full Text] [Related]
22. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Gadgeel SM; Lukas RV; Goldschmidt J; Conkling P; Park K; Cortinovis D; de Marinis F; Rittmeyer A; Patel JD; von Pawel J; O'Hear C; Lai C; Hu S; Ballinger M; Sandler A; Gandhi M; Fehrenbacher L
Lung Cancer; 2019 Feb; 128():105-112. PubMed ID: 30642441
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
26. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Fehrenbacher L; von Pawel J; Park K; Rittmeyer A; Gandara DR; Ponce Aix S; Han JY; Gadgeel SM; Hida T; Cortinovis DL; Cobo M; Kowalski DM; De Marinis F; Gandhi M; Danner B; Matheny C; Kowanetz M; He P; Felizzi F; Patel H; Sandler A; Ballinger M; Barlesi F
J Thorac Oncol; 2018 Aug; 13(8):1156-1170. PubMed ID: 29777823
[TBL] [Abstract][Full Text] [Related]
27. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Felip E; Burotto M; Zvirbule Z; Herraez-Baranda LA; Chanu P; Kshirsagar S; Maiya V; Chan P; Pozzi E; Marchand M; Monchalin M; Tanaka K; Tosti N; Wang B; Restuccia E
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1142-1155. PubMed ID: 33788415
[TBL] [Abstract][Full Text] [Related]
28. A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma.
Economopoulou P; Kotsantis I; Bamias A
Expert Opin Drug Saf; 2020 Aug; 19(8):955-960. PubMed ID: 32657630
[TBL] [Abstract][Full Text] [Related]
29. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
30. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
Masters JC; Khandelwal A; di Pietro A; Dai H; Brar S
CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):458-468. PubMed ID: 35166465
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
32. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
34. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
37. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E; Moreno V; Morgensztern D; Curigliano G; Rutkowski P; Trigo JM; Calvo A; Kowalski D; Cortinovis D; Plummer R; Maio M; Ascierto PA; Vladimirov VI; Cervantes A; Zudaire E; Hazra A; T'jollyn H; Bandyopadhyay N; Greger JG; Attiyeh E; Xie H; Calvo E
Cancer Chemother Pharmacol; 2022 Apr; 89(4):499-514. PubMed ID: 35298698
[TBL] [Abstract][Full Text] [Related]
38. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.
Stroh M; Winter H; Marchand M; Claret L; Eppler S; Ruppel J; Abidoye O; Teng SL; Lin WT; Dayog S; Bruno R; Jin J; Girish S
Clin Pharmacol Ther; 2017 Aug; 102(2):305-312. PubMed ID: 27981577
[TBL] [Abstract][Full Text] [Related]
39. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
